Search hospitals > Michigan > Ann Arbor
VA Ann Arbor Healthcare System, Ann Arbor, MI
Claim this profileAnn Arbor, Michigan 48105
Global Leader in Lung Cancer
Global Leader in Prostate Cancer
Conducts research for Diabetes Mellitus
Conducts research for Diabetes
Conducts research for Post-Traumatic Stress Disorder
254 reported clinical trials
24 medical researchers
Summary
VA Ann Arbor Healthcare System, Ann Arbor, MI is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Lung Cancer, Prostate Cancer, Diabetes Mellitus, Diabetes, Post-Traumatic Stress Disorder and other specialties. VA Ann Arbor Healthcare System, Ann Arbor, MI is involved with conducting 254 clinical trials across 334 conditions. There are 24 research doctors associated with this hospital, such as Michelle Mierzwa, M.D., David Elliott, Nithya Ramnath, MBBS, and Paul N Pfeiffer, MD MS.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage IIA
Stage IIB
2Prostate Cancer
Global LeaderStage IV
MLH1 positive
MSH2 positive
Top PIs
Michelle Mierzwa, M.D.University of Michigan Rogel Cancer Center2 years of reported clinical research
Studies Oropharyngeal Cancer
Studies Squamous Cell Carcinoma
4 reported clinical trials
10 drugs studied
David ElliottVA Ann Arbor Healthcare System3 years of reported clinical research
Studies Prostate Cancer
Studies Celiac Disease
3 reported clinical trials
7 drugs studied
Nithya Ramnath, MBBSThe University of Michigan Rogel Cancer Center6 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
3 reported clinical trials
4 drugs studied
Paul N Pfeiffer, MD MSVA Ann Arbor Healthcare System, Ann Arbor, MI6 years of reported clinical research
Studies Loneliness
Studies Blood Thinners
3 reported clinical trials
6 drugs studied
Clinical Trials running at VA Ann Arbor Healthcare System, Ann Arbor, MI
Prostate Cancer
Lung Cancer
Cancer
Chronic Pain
Parkinson's Disease
Colorectal Cancer
Diabetic Kidney Disease
Fanconi Anemia
Hepatocellular Carcinoma
Acute Viral Respiratory Infection
Docetaxel + Hormone Therapy
for Prostate Cancer
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Recruiting2 awards Phase 35 criteria
Pembrolizumab
for Prostate Cancer
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.
Recruiting2 awards Phase 23 criteria
Carboplatin vs Olaparib
for Prostate Cancer
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Recruiting1 award Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at VA Ann Arbor Healthcare System, Ann Arbor, MI?
VA Ann Arbor Healthcare System, Ann Arbor, MI is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Lung Cancer, Prostate Cancer, Diabetes Mellitus, Diabetes, Post-Traumatic Stress Disorder and other specialties. VA Ann Arbor Healthcare System, Ann Arbor, MI is involved with conducting 254 clinical trials across 334 conditions. There are 24 research doctors associated with this hospital, such as Michelle Mierzwa, M.D., David Elliott, Nithya Ramnath, MBBS, and Paul N Pfeiffer, MD MS.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.